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Abstract
Background—HIV-infected adults are at increased risk of severe malaria and death. Malaria 
prevention in people living with HIV (PLHIV) consists of several interventions, including 
cotrimoxazole (CTX) prophylaxis and insecticide-treated nets (ITNs). We conducted a systematic 
review of the available evidence.
Methods—MEDLINE, EmBase, Global Health, CINAHL, SOCA, and African Index Medicus 
were used to identify articles relevant to the CTX prophylaxis and ITNs interventions from 1995 
to July 2014. For each individual study, we assessed the quality of evidence and the impact of the 
2 interventions on the outcomes of mortality, morbidity, retention in care, quality of life, and/or 
prevention of ongoing HIV transmission. For each outcome, we summarized the quality of the 
overall body of evidence, the expected impact, and costing and cost-effectiveness (CE).
Findings—The overall quality of evidence regarding malaria-related morbidity was rated as 
“good” for CTX prophylaxis and “fair” for ITN use; the expected “impact” of these interventions 
on morbidity was rated “high” and “uncertain,” respectively. Three studies that addressed the 
costing and CE of ITN provision for malaria prevention in PLHIV consisted of 2 full “level 1” and 
1 partial “level 2” economic evaluations.
Conclusions—CTX prophylaxis is effective in reducing malaria-related morbidity among 
PLHIV. Limited evidence is available with respect to the impact and the CE of ITN use and/or 
provision in this population.
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INTRODUCTION
There are important interactions between HIV and malaria at both the population and 
individual levels.1 In 2012, there were 2.3 million new HIV infections globally (1.9–2.7 
million) and 1.6 million (1.4–1.9 million) AIDS-related deaths2; in the same year, an 
estimated 207 million cases of malaria (uncertainty interval: 135–287 million) caused 
approximately 627,000 deaths (uncertainty interval: 473,000–789,000).3 People living with 
HIV (PLHIV) are at increased risk for clinical malaria and may be at higher risk for 
treatment failure,4 and the adverse effects of malaria (anemia, low birth weight, preterm 
delivery) are amplified, particularly in pregnant women with HIV.5–8 Thus, identification of 
the best methods for reducing the incidence of malaria in adults with HIV infection could 
improve clinical and public health outcomes, especially in areas where both diseases are 
highly prevalent.
On World AIDS Day 2014, the World Health Organization (WHO) released a supplement to 
the 2013 “WHO consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection,”9 in which it provides an updated set of recommendations 
regarding cotrimoxazole (CTX) prophylaxis among PLHIV.10 The WHO states that “CTX 
prophylaxis is recommended for adults (including pregnant women) with severe or advanced 
HIV clinical disease (WHO stages 3 or 4) and/or with CD4 ≤350 cells per cubic millimeter. 
In settings where malaria and/or severe bacterial infections are highly prevalent, CTX 
prophylaxis should be initiated regardless of CD4 cell count or WHO stage.” The WHO also 
states that “CTX prophylaxis may be discontinued in adults (including pregnant women) 
with HIV infection, who are clinically stable on antiretroviral therapy (ART), with evidence 
of immune recovery and virologic suppression. In settings where malaria and/or severe 
bacterial infections are highly prevalent, CTX prophylaxis should be continued regardless of 
CD4 cell count or WHO clinical stage.”10
To reduce the risks associated with placental malaria, WHO recommends that HIV-infected 
pregnant women (as well as uninfected pregnant women and women whose HIV status is 
unknown) receive intermittent malaria preventive treatment during pregnancy (IPTp), 
although per WHO's 2006 guidance for CTX prophylaxis among PLHIV,11 and WHO's 
2013 policy brief for the implementation of IPTp using sulfadoxine–pyrimethamine (IPTp-
SP) to prevent malaria among pregnant women,8 IPTp is not required in pregnant women on 
CTX. This recommendation reflects the potential toxicity of combining CTX with other 
sulfa-based medications used for IPTp (eg, Sulfadoxine-pyrimethamine).8,11
This review aims at assessing the quality of evidence related to the efficacy of CTX 
prophylaxis for malaria prevention among HIV-infected adults, including pregnant women, 
and will address the question of whether CTX provided for general prophylaxis in women 
with HIV is adequate for the prevention of malaria-related morbidity.
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Consistent and correct use of insecticide-treated nets (ITNs) is another key intervention for 
malaria prevention. ITNs, including long-lasting insecticidal nets (LLINs), reduce the 
incidence of malaria and associated morbidity, particularly among children and pregnant 
women (the most susceptible groups of populations to malaria and its consequences),12 and 
have successfully contributed to the reduction in malaria and all-cause mortality over the 
past decade.13,14
The WHO's “Recommendations for Achieving Universal Coverage with Long-Lasting 
Insecticidal Nets in Malaria Control” (September 2013) emphasize the need to ensure that 
all populations at risk of malaria have access to ITNs.14 The WHO also recommends that 
existing public health programs (eg, combined mass distribution and immunization 
campaigns) should be leveraged and used as platforms to maximize efforts to achieve 
“universal coverage” of ITNs.15
In line with the other papers in this JAIDS supplement, this review summarizes currently 
available information about CTX prophylaxis and ITNs as malaria prevention in PLHIV and 
their impact on key outcomes. Because the focus of this supplement is on adult patients with 
HIV, we include only literature pertinent to the adult population. We did not address indoor 
residual spraying and prompt and effective case management of malaria illness that targets 
adults, some of whom may be HIV infected, nor did we address malaria prevention in 
children.
METHODS
We conducted a search of 6 medical literature databases—MEDLINE, EmBase, Global 
Health, CINAHL, SOCA, and African Index Medicus—to identify articles relevant to the 
use of CTX prophylaxis and ITNs/LLINs for malaria prevention interventions from 1995 to 
July 2014. A more detailed description of the search terms applied and the geographic filters 
used can be found in “Evaluation of evidence for impact of HIV care and support 
interventions in resource-limited countries: Introduction” in this Supplement.16 Specific 
additional search terms were used (“MALARIA” or “MALARIAE” or “MALARIAL” or 
“MALARIALS” or “MALARIOUS” or “MALARI”).
Search outputs (titles and abstracts) were reviewed by the authors to identify potentially 
relevant studies. Papers that appeared to contain relevant data were read in their entirety; 
included articles (1) studied PLHIV, (2) were conducted in developing countries (low- or 
middle-income), (3) used a CTX prophylaxis intervention or insecticide-treated nets for 
prevention of malaria, and (4) reported on at least 1 of the 5 outcomes of interest (mortality, 
morbidity, retention in HIV care, quality of life, or prevention of HIV transmission) or on 
costing or cost-effectiveness (CE). Those that satisfied criteria for inclusion were abstracted 
and summarized on the basis of study design [eg, randomized control trial (RCT) and cohort 
study], comparison group(s), number of participants, and assessment of impact on the 
outcome(s) of interest [expressed as hazard ratios (HR), odds ratios (OR), incidence rate 
ratios (IRR), or relative risk (RR) and the respective 95% confidence intervals (CIs) if 
available]. An assessment of the quality of each study was made on the basis of study 
design, number of participants, and internal and external validity and rated as “strong,” 
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“medium,” or “weak.” More details of the assessment of quality are described in 
“Evaluation of evidence for impact of HIV care and support interventions in resource-
limited countries: Introduction.”16 Health economic studies were assessed based on an 
agreed-upon set of categories as follows: level 1 full economic evaluation (includes either 
cost-effectiveness analysis, cost–utility analysis, cost–benefit analysis), level 2 partial 
economic evaluations (ie, cost analysis, cost-description studies, cost–outcome descriptions), 
or level 3 randomized trials and studies reporting more limited information, such as 
estimates of resource use or costs associated with intervention(s) and comparator(s).
Because of the heterogeneity of study populations, study methods, settings, and outcomes, 
we did not perform quantitative synthesis of study results overall. However, we rated the 
overall quality of the body of evidence related to each outcome as “good,” “fair,” or “poor” 
based on criteria agreed on a priori and described in the introductory paper. Similarly, the 
expected impact on each outcome was rated as “high,” “medium,” “low,” or “uncertain.” 
These criteria are described in “Evaluation of evidence for impact of HIV care and support 
interventions in resource-limited countries: Introduction.”16
RESULTS
Searches identified 4061 unduplicated abstracts of which 73 appeared to contain pertinent 
information and were therefore read in their entirety to determine whether they satisfied 
criteria for inclusion (Fig. 1). Twenty-two articles met inclusion criteria. Morbidity (variably 
defined across reviewed articles) was the only outcome addressed in the included articles; 
none of the 22 addressed mortality, retention in care, quality of care, or HIV transmission. 
Table S1 (see Supplemental Digital Content, http://links.lww.com/QAI/A656) summarizes 
the study design, sample size, findings, and quality of evidence rating of the 22 articles 
meeting final inclusion criteria.
The included studies had a wide variety of statistical designs and analyses, including 5 
RCTs,17,19,20,24,28 13 observational studies (OSs),18,21–23,26,27,29–35 1 systematic review 
(SR),25 and 3 health economics studies (see Table S1, Supplemental Digital Content, http://
links.lww.com/QAI/A656).36–38
The 22 studies varied with respect to the participants’ ART status. Of the 20 assessed 
individual studies (excluding the SR and 1 study that did not report on ART status),18,25 14 
(including 4 RCTs,19,20,24,28 9 OS,21,23,27,29–34 and 1 CE study38) enrolled participants on 
ART; 6 studies included participants not on ART (1 RCT,17 3 OS,22,26,31,35 and 2 CE 
studies36). Of the 19 included studies that addressed malaria-related morbidity outcomes 
(excluding the 3 costing and CE studies), 17 studies addressed CTX prophylaxis17–33; 4 
studies addressed provision and/or use of ITNs32–35 (including 2 studies that also addressed 
CTX prophylaxis32,33 and 2 that addressed ITN use alone).34,35 The 3 health economics 
studies also addressed ITNs.
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CTX Prophylaxis for Malaria Prevention (Excluding Costing and CE Studies,36–38 the SR,25 
and a Study That Did Not Report on the ART Status18) (n = 15)
Summary of Results of Individual Studies in Persons Who Did Not Receive 
ART (n = 4)—The study by Anglaret et al,17 an RCT in which malaria was addressed as a 
secondary outcome, reported an estimated malaria HR of 0·16 (0.04–0.73) among 
participants on CTX for morbidity events defined as “at least 1 severe malaria event.” 
Mermin et al26 (2004), in a longitudinal prospective study that aimed at assessing the 
association between CTX prophylaxis and morbidity (including malaria), mortality, CD4 
cell count, and viral load in adult PLHIV, showed an estimated 72% reduction in malaria 
incidence in enrollees on CTX. Reduction in malaria-related morbidity was found in both 
studies, irrespective of CD4 cell count. The study by Hamel et al was a prospective, open-
label, non-RCT, whose main purpose was to assess the potential impact of daily CTX on the 
emergence of “significant changes in antifolate and CTX resistance among common 
organisms,” including Plasmodium falciparum. HIV-infected subjects with CD4 cell count 
<350 per microliter (and receiving CTX) had an estimated 90% decrease in “incidence 
density” of “first or only infection” with P. falciparum compared with HIV-infected persons 
with CD4 cell count >350 per microliter (who were not receiving CTX) (adjusted rate ratio: 
0.10, 95% CI: 0.07 to 0.15, P < 0.025). The “incidence density” for “all episodes of P. 
falciparum parasitemia” was found to be reduced as well. This protective effect against P. 
falciparum infection among enrollees who received CTX did not change after adjusting for 
factors that included “prior P. falciparum parasitemia, IPTp-SP, ITN use, and housing type, 
in Poisson regression models” (P < 0.001).22
The study by Watera et al,31 an OS involving a historical comparison, did not show an effect 
of CTX prophylaxis on frequencies of “febrile and other morbidity event rates.” It did 
however show a reduction in the incidence of malaria (IRR: 0.31, 95% CI: 0.13 to 0.72).31
Summary of Results of Individual Studies in Persons Who Received ART (n = 
11)
Comparison “On CTX” vs. “Off CTX” (n = 4): Walker et al30 estimated the effects of 
CTX prophylaxis on “clinical outcomes” (including malaria) in a retrospective study, which 
enrolled HIV-infected ART-naive adults who were started on ART, with CD4 cell counts 
<200 per microliter. This observational analysis used data from the “routine versus clinically 
driven laboratory monitoring of HIV antiretroviral therapy in Africa” (DART) study, 
conducted in 2 centers, in Uganda and in Zimbabwe. Because of low malaria endemicity in 
Zimbabwe, the analysis of the effect of CTX on malaria was confined to Uganda. The study 
showed a statistically significant reduction in the frequency of malaria with diagnosis based 
on either symptoms or positive microscopy, in persons on CTX (OR: 0.74, 95% CI: 0.63 to 
0.88, P = 0.0005); the effect was sustained until 72 weeks of follow-up [between 48 and 72 
weeks on ART, persons receiving CTX prophylaxis had an OR of developing malaria of 0.50 
(95% CI: 0.33 to 0.74, P = 0.001)].30 Mermin et al (2006) was a 4-phase prospective 
longitudinal study whose primary purpose was to address the effect of ART on the frequency 
of “clinical malaria” in PLHIV and to determine the “additive effects” of CTX prophylaxis, 
ART, and ITNs. The study showed a statistically significant association between CTX 
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prophylaxis and reduced malaria incidence, defined as a febrile episode combined with a 
positive microscopic examination (adjusted IRR: 0.24, 95% CI: 0.15 to 0.38).32
The study by Iliyasu et al33 was a cross-sectional study whose primary aim was to assess the 
“prevalence and predictors” (including CTX prophylaxis and ITNs use) of malaria among 
adult PLHIV. Most of the respondents in this study (86.0%) were receiving CTX prophylaxis 
and 53.5% reported use of ITNs. The study did not demonstrate a significant difference in 
prevalence of “clinical malaria” (symptomatic parasitemia) among those who reported use of 
CTX prophylaxis, compared with those not having been on CTX prophylaxis (adjusted odds 
ratios (aOR): 1.27, 95% CI: 0.98 to 1.64, P = 0.13).33 Statistically significant differences 
were, however, identified using a multivariate analysis aimed at addressing potential 
associations between reported “clinical malaria” with baseline CD4 cell count <350 per 
microliter vs. >600 per microliter and non-use of ITNs (aOR: 2.41, 95% CI: 1.23 to 3.74, P 
= 0.023; and 1.97, 95% CI: 1.17 to 2.85, P = 0.017, respectively).33
Saracino et al,29 in a prospective longitudinal study, enrolled consecutively hospitalized 
adults who received “HIV testing, malaria blood smear, and, in a subgroup of patients, a 
rapid malaria test (RDT).” The study aimed at assessing the association between a positive 
malaria blood smear and/or RDT and the prevalence of “clinical malaria” (symptomatic 
parasitemia) with concomitant HIV infection and, secondarily, with the use of CTX and/or 
ART. 66.7% of enrollees were HIV positive and 35.4% of HIV-positive patients reported 
having a CTX prophylaxis prescription at the time of admission. The study showed a 
statistically significant association between CTX prophylaxis and positive malaria testing 
(OR: 0.20, 95% CI: 0.14 to 0.61, P < 0.001).29
CTX and Continuation/Discontinuation Individual studies (n = 2): The study by 
Campbell et al19 was an RCT in which HIV-infected persons stable on ART and with CD4 
cell counts above 200 per microliter were assigned to either continuation or discontinuation 
of CTX prophylaxis. Participants were assessed primarily for malaria and diarrhea-related 
outcomes. Enrollees who discontinued CTX prophylaxis were at a significantly higher risk 
of developing clinical malaria compared with those who continued CTX prophylaxis (RR of 
malaria 32.5, 95% CI: 8.6 to 275.0, P < 0.001). This study was stopped in its fourth month, 
as recommended by the Data Safety and Monitoring Board (DSMB); consequently, it was 
impossible to exclude a “short-lived rebound effect” as an explanation of the increased 
incidence of malaria illness.19 “Rebound effects” are thought to be a result of an 
“impairment of the immunity protective effect,” as a consequence of the use of antimalarial 
therapies39–41 (it has been suggested that the role of “persisting asymptomatic and 
polyclonal P. falciparum infections,” which occur in the absence of malaria prophylaxis in 
settings of intense malaria transmission, could be a potential explanation of the observed 
“rebound effect” after the interruption of prophylaxis).41–43
The study by Polyak et al (an RCT) aimed to determine the impact of CTX prophylaxis 
discontinuation on morbidity among HIV-infected adults who had been on ART for more 
than 18 months and who had a CD4 cell count >350 per microliter (CD4 count at enrollment 
was estimated at 595 cells/μL, and median ART duration was 4.5 years).28 The primary end-
point consisted of a “composite of morbidity (malaria, pneumonia, and diarrhea) and 
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mortality.” Enrollees who discontinued CTX prophylaxis had a significantly higher risk of 
the predefined end-point compared with those who continued CTX prophylaxis (combined 
morbidity/mortality IRR: 2.27, 95% CI: 1.52 to 3.38, P < 0.001). Malaria, defined here as a 
febrile episode confirmed with either a positive RDT or smear examination, was deemed to 
be the “driver” of the higher risk finding (IRR estimated at 33.02, 95% CI: 4.52 to 241.02, P 
= 0.001).28
Comparison of CTX to Other Antimalarial Drugs Among Pregnant Women (n = 5): 
Five individual studies, including 2 RCTs20,24 and 3 OS,21,23,27 addressed the effect of CTX 
on malaria end-points in HIV-infected pregnant women, compared with either IPTp-SP or 
mefloquine (MQ). Klement et al24 (an RCT) assessed the risk of developing malaria in HIV-
infected pregnant women with a CD4 cell count >200 per microliter. The study compared 
the effectiveness of CTX prophylaxis with that of IPTp-SP in preventing malaria during 
pregnancy in a P. falciparum–endemic area in Togo. In the CTX arm, 75.4% of women did 
not develop malaria (defined as a thick blood smear or RDT-confirmed case of a 
symptomatic malaria episode) compared with 84.7% of women in the IPTp-SP arm. The 
difference was estimated at 9.3%, 95% CI: −0.53 to 19.1, not meeting the predefined “non-
inferiority” criterion. The authors did not conclude that CTX was inferior to IPTp-SP 
regarding malaria-free survival (the study was designed to assess “non-inferiority”), but the 
difference in point estimates of malaria-free rates suggests that CTX could potentially be 
inferior to IPTp-SP. It is noteworthy that the author did not report on the proportions of 
enrollees who received 2 vs 3 doses of IPTp-SP; the third dose of IPTp-SP was given “when 
possible.”24 It is therefore possible that CTX prophylaxis would have been shown to be 
inferior had the subjects received the WHO-recommended 3 doses of IPTp-SP.8
In the RCT conducted by Denoeud-Ndam et al,20 CTX was found to be non-inferior when 
compared with CTX plus MQ in preventing microscopically diagnosed placental malaria in 
HIV-infected women with CD4 cell counts <350 cells per microliter. However, using 
polymerase chain reaction (PCR)–based diagnosis, placental malaria was significantly less 
likely to be diagnosed in women who received CTX + MQ compared with those who 
received CTX only (0/105 and 5/103, respectively, P = 0.03).20
The study by Dow et al21 was a retrospective study whose main purpose was to assess the 
effect of CTX prophylaxis on malaria during pregnancy, low birth weight, and preterm birth 
in women enrolled in the “Breastfeeding, Antiretroviral, and Nutrition” RCT, which was 
conducted in Malawi between 2004 and 2009. The implementation of CTX prophylaxis 2 
years after the start of this RCT represented an opportunity to assess the effect of CTX 
prophylaxis. CTX prophylaxis was implemented in 2006. The analysis showed a statistically 
significant protective effect of CTX prophylaxis against malaria (defined as “the first 
episode after the second prenatal visit,” clinically diagnosed and laboratory-confirmed), as 
compared with IPTp (malaria HR: 0.35, 95% CI: 0.20 to 0.60). However, a “sensitivity 
analysis” of malaria rates in CTX-ineligible women (with CD4 counts >500/μL) in the 2 
time-periods indicated that women were at lower risk of malaria after 2006; after adjustment 
for time-period, CTX prophylaxis was no longer found to be protective against malaria (aHR 
0.66, 95% CI: 0.28 to 1.52).21
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In Kapito et al, data from a cross-sectional study that was conducted to assess the effects of 
iron supplementation on “maternal morbidities” were used to assess the prevalence of 
malaria parasitemia and anemia in HIV-infected pregnant women who received CTX 
prophylaxis, with or without IPTp-SP, compared with women who received IPTp-SP only. 
Women enrolled in this study were aged 15 or older, less than 34 weeks pregnant, and were 
attending a routine antenatal care routine visit. Participants were required to respond to a 
questionnaire and submit to a physical examination, followed by malaria laboratory testing 
(smear microscopy and PCR).23 Enrollees had a median CD4 cell count of 423 cells per 
microliter (ranging from 11 to 1528 cells/μL), use of nets was reported by 59.6% of enrolled 
women, and 48.5% of the women reported ART. After adjusting for potential confounders, 
women taking CTX, with or without IPTp-SP, were less likely to have “microscopic” or 
“PCR-detected” malaria infection, compared with women who received IPTp-SP alone 
(infection OR: 0.09, 95% CI: 0.01 to 0.66 and 0.43, 95% CI: 0.19 to 0.97, respectively). 
Possible confounding factors, such as “ITN use, ART use,” and the change in the newly 
implemented national malaria prevention guidelines, may have prevented a more accurate 
analysis and interpretation of the study's findings, a challenge that could not be addressed, 
given the non-randomization nature of this study.23
Newman et al conducted a cross-sectional study that aimed at comparing the prevalence of 
placental malaria in HIV-infected pregnant women receiving CTX prophylaxis with that in 
HIV-uninfected pregnant women receiving IPTp-SP. After adjusting for factors including 
“gravidity, age, and season at the time of delivery,” no significant difference was found in 
terms of placental malaria prevalence at delivery, between HIV-infected women who 
received CTX prophylaxis as compared with HIV-uninfected women on IPTp-SP.27
Systematic review addressing CTX prophylaxis malaria-related morbidity: In the study 
by Manyando et al,25 which included some of the individual studies in this 
review,23,26,27,30,32 CTX was found to reduce malaria incidence by 46%–97%.
Provision and Use of Insecticide-Treated Nets (Excluding Health Economics studies): 
Of the 19 studies that addressed malaria-related morbidity outcomes (excluding the 3 health 
economics studies), 4 studies addressed the use of ITNs.32–35
The study by Mermin et al32 (2006) was a 4-phase study in which 3 interventions (CTX 
prophylaxis, ART, and nets) were sequentially offered to participants who were enrolled at 
different points throughout the study's duration. CTX prophylaxis was found to have a 
protective effect against “clinical malaria” (“reported fever in the previous 2 days,” 
confirmed through both a thick and a thin smear exam). Malaria adjusted-IRR (aIRR) was 
estimated at 0.05, 95% CI: 0.03 to 0.08.32
A descriptive cross-sectional study reported by Olowookere et al34 enrolled a “convenience 
sample” of newly recruited PLHIV who were submitted to malaria screening, treated if 
diagnosed with malaria, educated about malaria infection, provided with an ITN, and finally 
evaluated for malaria infection on a monthly basis during a 3-month follow-up period. A 
decrease in prevalence of positive P. falciparum parasitemia from 59.7% at baseline to 5.1% 
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at the end of the 3-month period was observed. The authors did not report on a precise value 
of the effect estimate.34
The study by Walson et al was a prospective cohort study that assessed the potential effect of 
“LLINs and simple point-of-use water filters” on the slowing of HIV-1 disease progression. 
The study's 2 primary end-points consisted of “time to CD4 cell count <350 cells per 
microliter” and “a composite end-point of time to CD4 cell count <350 cells per microliter 
and non-traumatic death.” Enrollment criteria included “HIV-1 infection, age >18, absence 
of a history of ART, a CD4 cell count >350 per microliter, and WHO stage I or II disease.”35 
The study addressed malaria morbidity as a secondary end-point by measuring the incidence 
of both “self-reported” (symptomatic) and “laboratory-confirmed malaria.” Enrollees were 
followed for up to 24 months. Participants in the intervention cohort (receiving LLINs and 
water filters) were less likely to self-report malaria within the previous 3 months compared 
with participants in the control cohort (RR: 0.75, 95% CI: 0.60 to 0.93). “Clinically 
diagnosed” malaria was also less likely to be identified by a health care provider within the 
previous 3 months among subjects who received LLINs and water filters, compared with 
those who did not (RR: 0.66, 95% CI: 0.49 to 0.88). There was no difference in the use of 
CTX prophylaxis between the cohorts (99.7% and 99.8% in the intervention and in the 
control group of patients, respectively, P = 0.8).35 Finally, participants who received and 
used LLINs and point-of-use water filters were found to have a significantly lower risk of 
having their CD4 cell counts decline to below 350 cells per microliter (HR: 0.73, 95% CI: 
0.57 to 0.95).35
The study by Iliyasu et al33 was a cross-sectional study that primarily aimed at estimating 
the “prevalence and predictors of malaria infection among HIV-positive patients attending a 
referral center.” The study showed that “clinical malaria” (symptoms and parasitemia) was 
significantly associated with the non-use of ITN (aOR: 1.97, 95% CI: 1.17 to 2.85, P = 
0.017).33
Costing and Cost-effectiveness
CTX for Malaria Prevention: No relevant studies meeting the selection criteria for this 
review were found.
Provision of Insecticide-Treated Nets: Kern et al,38 in a study rated “level 1,” reported the 
“effectiveness, cost, and cost-effectiveness” of providing “LLINs and point-of-use water 
filters” to ART-naive HIV-infected adults and their family members. Data for this study were 
abstracted from an OS that enrolled 589 HIV-infected adults, conducted in Kenya, and 
which assessed the association between “LLITN use and water filters” and the progression 
of HIV-1 disease, as measured by “CD4 cell count decline” and/or “time to death.” Total 
costs averted were estimated at $34,975 [ART-related costs (because of delay in need for 
ART), costs averted by LLINs (malaria) and “costs averted” by water filters (diarrhea) were 
estimated at $24,395, $747, and $9,834, respectively]. A net cost savings of about US 
$26,000 was found for the intervention over 1.7 years. The authors concluded that the 
combined intervention cost of US $3100 per death averted or US $99 per disability-adjusted 
life year (DALY) averted, and that the estimated cost-effectiveness ratios were in the range 
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of cost-effectiveness ratios for other prevention interventions for the 3 addressed diseases 
(HIV/AIDS, malaria, and diarrhea). It is noteworthy that the combined prevention 
interventions including LLINs averted substantial costs in terms of new ART initiations 
during the intervention period. For instance, the costs averted from malaria per se are small 
but the value of CTX and LLINs in terms of delaying ART costs is potentially important.38
Kahn et al36 (2011), in a study rated “level 2,” provided cost information for bednet 
provision as part of an “Integrated Prevention Campaign,” which consisted of the provision 
of nets, filters, HIV testing, and condoms. The study helped determine the necessary 
resources needed for implementation of the campaign. Findings showed a “projected unit 
cost” per person served, by disease, estimated at $6.27 for malaria (nets and training), 
$15.80 for diarrhea (filters and training), and $9.91 for HIV (test kits, counseling, condoms, 
and CD4 testing at each site).36
Kahn et al37 (2012), a level 1–rated study, addressed the CE of the aforementioned 
“Integrated Prevention Campaign” using a “spreadsheet-based model.” Existing data 
regarding the impact of the each of the 3 assessed interventions (VCT, LLINs, and water 
filters) on morbidity and mortality, along with the available costing information from the 
same campaign (in the study of Kahn et al. 2011), were used to determine estimates of 
averted deaths, DALYs, and cost savings. The model-based analysis included added costs 
associated with potential earlier ART initiation as well. Per 1000 campaign beneficiaries, the 
provision of LLINs allowed for the aversion of 4.31 deaths, 1304 malaria episodes, 125 
DALYS, and $10,420 of costs. Findings were robust to the sensitivity analyses performed. 
Kahn et al37 concluded a more “favorable outcome” in their study, compared with the CE of 
existing published findings regarding malaria prevention–related interventions (a cost 
ranging from $2 to 15 per DALY averted44).
Quality of the Evidence and the Expected Impact on Mortality, Morbidity, and 
Retention in Care
CTX Prophylaxis: Of the 17 studies that addressed morbidity (including the 2 studies that 
addressed both CTX prophylaxis and ITNs use32,33), the quality of the evidence was rated as 
“strong” for 6 studies,17,19,20,24,25,28 “medium” for 10 studies,21–23,26,27,29,30,32–34 and 
“weak” for 1 study (Table 1; see Table S1, Supplemental Digital Content, http://
links.lww.com/QAI/A656).18 The overall quality of the evidence in these studies was rated 
as “good.” The expected impact of CTX prophylaxis on malaria-related morbidity reduction 
was rated as “high” (Table 1).
ITNs/LLINs Provision and Use: Data were very limited regarding the impact of ITNs/
LLINs provision and/or use on malaria morbidity reduction in HIV-infected persons. Four 
studies addressed morbidity32–35 (excluding the 3 health economics studies36–38 and 
including the 2 studies that addressed both ITNs use and CTX prophylaxis).32,33 The quality 
of each of the 4 studies was rated as “medium.” The overall quality of evidence was rated as 
“fair” and the impact of ITNs/LLINs was rated as “uncertain” (Table 1). The scarcity of the 
evidence did not allow for a more robust assessment of the potential impact of LLINs 
provision and/or use on malaria prevention.
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DISCUSSION
There is clear evidence that rates of malaria (particularly P. falciparum malaria) infection 
and illness in people with HIV are reduced by CTX prophylaxis. The overall impact on 
morbidity and mortality in HIV-infected persons is more likely to drive use of CTX than the 
specific issue of malaria prevention—these considerations are summarized in the 
accompanying CTX review in this supplement (Assessment of the Impact of Cotrimoxazole 
Prophylaxis on Key outcomes Among HIV-Infected Adults in Low- and Middle-Income 
Countries: A Systematic Review).45 However, there are important malaria-specific questions 
related to CTX prophylaxis that should be considered. These include the question of whether 
additional or alternate interventions should be considered for pregnant women to prevent 
clinical and placental malaria and whether continuation of CTX prophylaxis remains a 
priority in malaria-endemic areas when it is no longer a priority for the purposes of general 
prophylaxis (eg, following immune reconstitution as a result of ART) or when universal 
access to and use of LLINs have been achieved.
Our review did not specifically focus on the issue of prevention of placental malaria. 
However, based on the currently available evidence, CTX prophylaxis is associated with 
reductions in placental malaria among pregnant women with HIV and does not seem to be 
inferior to other available interventions.
An important question for programs is whether the impact of CTX on malaria rates should 
influence decisions about discontinuation of CTX prophylaxis. Although the literature does 
not demonstrate the long-term impact of CTX on disease rates in persons on ART, 
continuation of CTX needs to be considered. In malaria-endemic areas, CTX discontinuation 
is associated with a marked increase in malaria rates.
Although very limited, existing evidence suggests that CTX prophylaxis does not result in a 
population-level increase in resistance to medications commonly used for malaria prevention 
or treatment, particularly IPTp-SP.46–49 Furthermore, concerns about the potential of 
widespread use of CTX prophylaxis implementation to increase the risk of antifolate 
resistant malaria may be less relevant because of the significant progress achieved in recent 
years regarding access to the artemisinin-based combination therapies, especially those that 
are antifolate-free.3 Also, IPTp-SP seems to remain effective in preventing the adverse 
consequences of malaria on maternal and fetal outcomes in P. falciparum–endemic areas.8
Limitations and Research Gaps
As described in the accompanying review of CTX prophylaxis (Assessment of the Impact of 
Cotrimoxazole Prophylaxis on Key Outcomes Among HIV-Infected Adults in Low- and 
Middle-Income Countries: A Systematic Review), available evaluations of malaria 
prevention in HIV are heterogeneous in terms of design and, particularly with respect to 
background rates of malaria, the definitions for end-points and durations of follow-up (Table 
2). In the reviewed studies, malaria outcomes were defined variably (clinically, based on 
microscopy, rapid tests, and PCR), and assessment of the potential additional impact of 
LLINs to that of CTX prophylaxis was generally limited because of the non-availability of 
data related to quantified use of ITNs/LLINs. For instance, only 6 of the 17 individual 
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studies that assessed CTX prophylaxis impact on malaria have reported data on precise use 
of LLINs.22–24,28,33,34 However, 3 of the 4 studies that addressed impact of LLINs on 
malaria morbidity quantified the use of nets (Table 2).33–35
Moreover, it is difficult to evaluate the effectiveness of specific interventions that are 
provided in combination with other interventions (eg, vector control interventions including 
the use of ITNs and LLINs in combination with CTX prophylaxis and water filters). 
Evaluation of interventions that are provided in combination sometimes necessitates the use 
of creative study designs, such as the evaluation of sequential introduction of program 
elements.
The existing evidence showed non-inferiority of CTX prophylaxis compared with IPTp-SP 
(very likely 2 doses) for malaria prevention in HIV-infected pregnant women, especially in 
those with higher CD4 cell counts (≥350 cells/μL). However, more research is needed to 
better inform malaria prophylaxis policies for HIV-infected pregnant women by addressing 
the comparison of CTX prophylaxis to the effective provision of the “3-or-more-doses of 
IPTp-SP,” as recommended by the WHO for HIV-negative pregnant women in “moderate- 
and high-malaria transmission areas.”8 Studies should ascertain uptake of the “3-or-more-
doses of IPTp-SP” and allow for longer follow-up durations and more focus on malaria 
incidence and birth outcomes as measured by the primary end-point. Finally, more 
operational research and program evaluation quality data are needed to guide the 
implementation of both CTX prophylaxis and IPTp-SP in a well-coordinated manner.
Programmatic Considerations
In settings where HIV and malaria diseases burden is high, HIV and malaria control 
programs (including major donors and stakeholders) have the potential and the opportunity 
to greatly benefit from further leveraging their own resources and maximizing the impact of 
their investments. Effective partnerships and close collaboration between the 2 programs and 
with other programs, including maternal and child health programs, should be encouraged. 
Distribution of free LLINs using prenatal clinics as a platform has, for instance, the potential 
for better coverage in the most vulnerable populations, namely pregnant women and 
children, irrespective of their HIV status. Such an approach has the potential of benefiting 
both the general and the HIV-infected populations, mitigating the negative impact of 
recurrent administrative and programmatic duplications, allowing for a better coordinated 
and harmonized design and implementation of malaria prevention policies, and contributing 
to more efficient commodities supply mechanisms (eg, procurement of LLINs) and use of 
human resources.
CONCLUSIONS
Our review suggests a potentially high impact of CTX prophylaxis for malaria prevention in 
adult PLHIV, including pregnant women. The evidence similarly shows a potential higher 
risk of malaria when CTX is discontinued in areas with high malaria prevalence. Because of 
very limited evidence, the expected impact of ITNs distribution and use on malaria 
prevention in PLHIV seems uncertain.
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FIGURE 1. 
Study flow diagram. *Duplicate citations removed.
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TABLE 1
Summary of the Body of the Evidence From All Studies by Outcome
Overall Quality of Evidence Evidence From Economic 
Evaluation
Studies Overall Quality of the Body of 
Evidence
Expected Impact of 
the Intervention*
Studies, 
Number of 
Studies 
With 
Costing/C
E
Quality of 
Evidence 
From 
Economic 
Evaluation
Comments
Morbidity 22 
(including 
3 
economic 
studies)
Good (CTX prophylaxis for 
malaria prevention)
High (CTX 
prophylaxis for 
malaria prevention)
No 
economic 
studies for 
CTX 
prophylaxis
CTX for 
malaria 
prevention: 
no relevant 
study was 
found
Of the 22 studies, 5 
were RCTs,17,19,20,24,28 
13 were 
OS,18,21–23,26–30,32–35 1 
was a SR’ and 3 studies 
addressed exclusively 
costing and CE36–38
17 studies addressed 
the impact of CTX 
prophylaxis on the 
malaria-related 
morbidity 
outcome17–33
Of the 5 RCTs, 4 
enrolled participants on 
ART and 1 enrolled 
participants not on 
ART17
Of the 22 studies, 
only 2 assessed both 
CTX prophylaxis and 
the ITN 
intervention32,33
Of the 13 OS, 8 
enrolled ART 
patients21,23,26,29,30,32–34 
and 4 enrolled patients 
not on ART.22,26,31,35 
Information on ART 
status was unavailable 
for 1 OS18
Fair (ITNs/LLINs use/provision) Uncertain (ITNs use) 3 for ITNs 
provision/u
se
ITNs use 
intervention: 
Two LEVEL 
1 studies 
reported: 
Robust 
findings in 
terms of 
effectiveness, 
costs and CE 
of providing 
LLINs and 
point-of-use 
water filters 
to ART-naive 
HIV-infected 
adults and 
their family 
members, in 
the context of 
a multi-site 
study in 
Kenya.37
Very limited data on 
evidence that 
demonstrates the 
impact of ITNs on 
malaria morbidity 
reduction in the 
specific population of 
HIV-infected 
individuals32–35
CE of LLINs 
part of an 
integrated 
prevention 
campaign 
including 
targeting 
malaria, HIV 
and 
diarrhea.38
One LEVEL 
2 study 
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Overall Quality of Evidence Evidence From Economic 
Evaluation
Studies Overall Quality of the Body of 
Evidence
Expected Impact of 
the Intervention*
Studies, 
Number of 
Studies 
With 
Costing/C
E
Quality of 
Evidence 
From 
Economic 
Evaluation
Comments
provided a 
cost analysis 
information 
of bednet 
provision as 
part of a 
combination 
of three 
integrated 
interventions 
through a 
punctual 
campaign.36
Assessment of the expected impact of the intervention was based on published evidence. Additional considerations that would inform 
implementation decisions would have to take into account the CE information and country-specific contextual considerations.
*
The expected impact of the intervention was rated as high = intervention expected to have a high impact on the outcome; moderate = likely to 
have a moderate impact on the outcome; low = intervention expected to have a low impact on the outcome; and uncertain = available information is 
not adequate to assess estimated impact on the outcome.
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TABLE 2
F.U. Durations, Morbidity Definitions, Enrollment in Study Criteria, and ITNs Use
F.U. Duration Morbidity (Including 
Malaria) Definition When 
Applicable
Studies’ Enrollment Criteria ITNs Use
Anglaret et al17 Mean = 0.9 yrs Morbidity “potentially 
preventable by CTX,” 
including: infections with 
bacteria, toxoplasma, 
isospora, nocardia, 
Pneumocystis carinii, and 
malaria
Aged 18 yrs and older with HIV-1 or 
HIV-1 and HIV-2 dual seropositivity at 
stages 2 or 3 of the WHO staging 
system
Not reported
Bulabula et al18 Cross-sectional 
study (duration of 
recruitment: 0.3 
yrs)
Malaria prevalence 
(parasitemia): Positive smear 
for Plasmodia
HIV-infected and non-infected 
individuals
Not reported
Campbell et al19 F.U. duration: 0.3 
yrs
“Smear-positive episode of 
fever” and all cases were 
treated. Densities of >1250 
parasites/μL (implying high 
likelihood that malaria was 
the cause of the “febrile 
illness,” “not incidental 
parasitemia”
Individuals aged 18 or older, with CD4 
cell count below 250 cells/μL or WHO 
stage III or IV
Yes: ITNs 
provided free of 
charge to all 
participant 
women but no 
data on use
Denoeud-Ndam et al20 F.U. duration: from 
16- to 28-wk 
gestation until birth
Thick and thin blood smears 
stained with Giemsa and read 
by 2 independent 
microscopists, with 
conciliation of discrepancies 
by a third reader
HIV-infected pregnant women aged 18 
or older and living permanently in the 
study area were enrolled between 16 
and 28 wks of gestation
Yes: provided to 
all enrolled 
women but no 
data on use
Slide negative after 200 high-
power fields were read
Positive slides: parasite 
density was determined per 
500 leukocytes (assumption 
of an average leukocyte 
count of 8000 cells/μL)
Dow et al21 F.U. duration: 0.54 
yrs since study 
second antenatal 
visit, to assess 
probability of 
malaria-free 
survival
“First episode after the 
second prenatal visit” based 
on a positive blood smear 
with malaria symptoms
HIV-infected pregnant women, ART-
naive, at least 14 yrs of age and less 
than 30 wk of gestation eligible for 
enrollment if hemoglobin levels >7 
g/dL, CD4 cell count >250 cells/
μL(>200 cells/μL before July 24, 2006)
Yes: no data on 
number provided 
and used
Hamel et al22 Median = 0.46 yrs; 
mean = 0.38 yrs
“Clinical malaria”: 
Plasmodium falciparum 
infection with measured or 
reported fever or P. 
falciparum infection with 
parasite density ≥400 
parasites/μL regardless of 
fever
Subjects aged 15 or older, who agreed 
to HIV testing, not severely ill nor in 
the first trimester of pregnancy, and 
who were not taking daily antibiotics 
for the treatment of a chronic illness 
(excluding tuberculosis)
Yes: data on use 
available
Kapito-Tembo et al23 Cross-sectional Presence of malaria parasites 
on microscopy
HIV-infected pregnant women aged 15 
or older and with gestation over 34 wk 
attending the hospital's ANC clinic. 
Women with immediate life-threatening 
medical and obstetric conditions 
excluded
Yes: data on use 
available
“PCR-detected malaria 
infection” was defined as 
positive result of PCR for 
malaria regardless of 
microscopy results
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F.U. Duration Morbidity (Including 
Malaria) Definition When 
Applicable
Studies’ Enrollment Criteria ITNs Use
Klement et al24 F.U. duration: From 
14- to 28-wk 
gestation until birth
“Positive biological test,” a 
body temperature ≥37.5°C, 
and at “least 1 clinical sign”: 
asthenia, headache, myalgia, 
or abdominal pain
HIV type 1–infected pregnant women 
(≤28 wk of gestation, CD4 count >200 
cells/μL, hemoglobin level 7 g/dL or 
greater)
Yes: all enrolled 
women received 
ITNs and data 
on use available
Manyando et al25 SR SR (see individual studies 
elsewhere in this table)
SR (see individual studies elsewhere in 
this table)
SR (see 
individual 
studies 
elsewhere in this 
table)
Mermin et al26 (2004) Median FU time for 
individuals with 
HIV infection, 
before CTX: 0.42 
yrs (IQR 0.4–0.44), 
and during CTX: 
1.46 yrs (1.29–1.47)
Fever and a thick smear 
consistent with the presence 
of plasmodia
HIV-1–infected individuals and their 
HIV-negative household members
Not reported
Newman et al27 Cross-sectional 
study (recruitment 
period: February 
2008 and February 
2009)
Positive placental blood 
smear: parasite density ≥1 
parasite/μL
HIV-infected and infected pregnant 
women
Not reported
Polyak et al28 F.U. duration: 1 yrs RDT or smear positive with 
fever
HIV-infected adults who had been on 
ART for >18 mo and had CD4 count 
>350/μL
Yes: data on use 
available
Saracino et al29 Cross-sectional 
study (from 
November to 
December 2010)
MBS or RDTs All adult patients (>15 yrs, according to 
the hospital policy) consecutively 
hospitalized
Not reported
MBS: parasitemia was 
assessed using a semi-
quantitative method
Walker et al30 Median: 4.9 yrs New WHO stage 4 events, 
new or recurrent WHO stage 
3 or 4 events, and malaria 
(“clinical” or “microscopic” 
diagnosis)
From the “DART RCT of management 
strategies” in HIV-infected 
symptomatic (WHO stage 2–4) adults 
aged 18 or more, starting ART with 
CD4 counts <200 cells per microliter, 
who reported no previous ART apart 
from to prevent mother-to-child 
transmission
Not reported
Watera et al31 Person-yrs of F.U.: 
1463 (before and 
after CTX 
prophylaxis 
introduction)
Participants who visited the 
clinic with a fever 
(temperature, “greater or 
equal to 37.5°C”) were 
examined by a physician who 
made a diagnosis (primary 
outcomes) based on 
“reported symptoms, 
observed signs, and the 
results of laboratory tests”
HIV-seropositive adults (aged older 
than 15 yrs)
Not reported
Mermin et al32 (2006) Median F.U. before 
CTX was 0.42 yrs
Reported fever and “parasites 
seen on thick smear”
HIV-infected individuals aged 18 yrs or 
older
Yes: data on 
provision 
available. Not 
reported on use
During CTX 1.45 
yrs, during CTX 
and ART: 0.34 yr
“Parasite density” calculated 
with WBC count of 8000/μL
During CTX, ART, 
and nets: 1.53 yrs
Iliyasu et al33 Cross-sectional 
study design (1-mo 
recruitment period)
Episode of fever confirmed 
as malaria when on blood 
film examination
HIV/AIDS patients attending the HIV 
clinic over a 1-mo period (June 1–30, 
2012). All adults (≥18 yrs) with HIV 
infection with at least 1 clinic visit were 
Yes: half of all 
respondents 
(53.5%) 
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 April 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hassani and Marston Page 22
F.U. Duration Morbidity (Including 
Malaria) Definition When 
Applicable
Studies’ Enrollment Criteria ITNs Use
included in the study (treatment-
experienced or naive)
admitted to 
using ITN
Olowookere et al34 Cross-sectional 
study (recruitment 
period from June to 
December 2010)
Positive blood film New PLWHIV (irrespective of age) Yes: data on use 
available
Walson et al35 Mean F.U. time: 
control cohort: 1.85 
yrs; intervention 
cohort: 1.67 yrs
Malaria: fever (>38.8°C) and 
positive RDT and/or 
“malaria thin and thick 
smear”
HIV-1–infected adults ineligible for 
ART initiation
Data on 
provision and 
use available
Diarrhea: “3 or more 
episodes of watery stools in a 
day”
Proportions of 
those who both 
have a net and 
sleep under it: 
“intervention 
group”: 97.3%
“Control group”: 
82.4% (<0.001)
Kahn et al36 (2011) 
Costing
Costing study “Projected unit cost” per 
person served, by disease, 
estimated at $6.27 for 
malaria (nets and training)
CE study Yes: data 
available for 
provision only. 
Not on use
Kahn et al37 (2012) CE CE study Per 1000 campaign 
beneficiaries, provision of 
LLINs led to the aversion of 
4.31 deaths, 1304 malaria 
episodes, 125 DALYS, and 
$10.420 of costs
CE study Yes: data 
available for 
provision only. 
Not on use
Kern et al38 CE Costing study “Net cost savings” of about 
US$ 26,000 for the 
intervention, over 1.7 yrs CE 
study
Costing study Yes: data 
available from 
Walson et al 
2013
DART, development of antiretroviral therapy; F.U., follow-up; MBS, malaria blood smear; RDT, rapid diagnostic test.
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